Tapping into a market of more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico in 2024 and fueling International Sales Access Across Latin America Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the establishment of its subsidiary, MangoRx Mexico, which will act as the lynchpin of the Company’s Mexican and expanded Latin American sales strategies for its Mango ED products.

2024年，墨西哥全国拥有40000多家药店、零售店和便利店，2023年12月6日，德克萨斯州达拉斯（Global NEWSWIRE）——Mangoceuticals，Inc.（纳斯达克股票代码：MGRX）（“MangoRx”或“公司”），一家专注于开发、营销、，并通过安全的远程医疗平台销售各种男性健康和保健产品，包括其独特配方的毛发生长产品（“GROW”）和勃起功能障碍（ED）药物（“Mango”），很高兴宣布成立其子公司MangoRx Mexico，这将成为该公司在墨西哥和拉丁美洲扩大芒果ED产品销售战略的关键。

The Company has engaged one of the largest international law firms, Diaz Reus International Law Firm, to establish its subsidiary presence in Mexico. With offices across five continents, Diaz Reus represents major Fortune 500 brands including Oracle, Nissan, Sony, and Allianz, to name a few. “This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MangoRx’s Co-Founder and CEO.

该公司聘请了最大的国际律师事务所之一Diaz Reus international law Firm在墨西哥建立其子公司。Diaz Reus在五大洲设有办事处，代表着包括甲骨文、日产、索尼和安联在内的世界500强主要品牌。MangoRx联合创始人兼首席执行官雅各布·科恩（JacobCohen）指出：“这对我们未来的增长轨迹有着巨大的影响，有几个重要原因。”。

“First, ED medications - such as branded and generic Viagra (Sildenafil) and Cialis (Tadalafil) - are available to consumers over-the-counter in Mexico. That presents increased margin and sales volume potential for what we already produce and market here in the United States. Second, Mexico is a completely untapped market as our research indicates that we will be the only company offering an ED product in a flavored rapid-dissolve tablet (RDT).” Next steps include establishing a manufacturing partner, applying for, and achieving certification with, the Comisión Federal para la Protección contra Riesg.

“首先，ED药物-例如品牌和仿制药伟哥（西地那非）和夏利斯（他达拉非）-在墨西哥的非处方药消费者可以使用。这意味着我们已经在美国生产和销售的产品的利润率和销量潜力增加。其次，墨西哥是一个完全未开发的市场，因为我们的研究表明，我们将是唯一一家在风味速溶片（RDT）中提供ED产品的公司。”接下来的步骤包括建立制造合作伙伴，申请联邦反保护委员会（Comision Federal para la Protección contra Riesg）并获得认证。

Attachment

附件

Mangoceuticals, Inc.

Mangoceuticals公司。